Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks is supported by a de-risked commercial catalyst in zanidatamab, now FDA-approved in 1L HER2-positive GEA, with Phase 3 data showing median PFS of 12.4 months versus 8.1 months and an OS benefit of 26.4 months versus 19.2 months in the triplet arm. The company also benefits from a sizable pro-forma cash position of $572.5MM, a share buyback program, and royalty economics that should strengthen materially as Jazz guides zanidatamab toward $3–5B in peak sales and as royalties step up with higher annual net sales. Beyond the lead asset, advancing programs like ZW191, ZW251, and the differentiated pan-RAS inhibitor ADC platform, along with acquisition-related royalty streams and upcoming milestones, give the stock multiple paths to value creation.

Zymeworks is viewed negatively because its value depends heavily on zanidatamab and other pipeline assets that face high clinical, competitive, and regulatory failure risk, while the company itself acknowledges that most drugs entering clinical development never reach the market. The bearish case assumes zanidatamab’s commercial launch is underwhelming, with only a 10% POS for global royalties and milestones in BTC and GEA and no platform value, which underscores how much of the valuation rests on a single asset and uncertain approval outcomes. In addition, capital intensity, possible dilution, manufacturing scale-up challenges, and weaker-than-expected market uptake could pressure the stock even if some trials progress, leaving significant downside if results or FDA timing disappoint.